PHSI-BRG
PHSI-BRG
Home
Staff
Sarah Al Ashmori
Andy Bryant
Thomas Chadwick
Svetlana Cherlin
Mike Cole
Holly Fisher
Tony Fouweather
Shaun Hiu
Dorcas Kareithi
Ann Breeze Konkoth
Nan Lin
Jingky Lozano-Kuehne
Helen Mossop
Ellen Moss
Aritra Mukherjee
Jérémie Nsengimana
Vicky Ryan
Marzieh Shahmandi
Moha Shojaei
Dawn Teare
James Wason
Faye Williamson
Nina Wilson
Sylvia Zhang
PhD students
Ruqayya Azher
Nicole Cizauskas
Laura Etfer
Niamh Fitzgerald
Raiann Hamshaw
Pela Okorie
Samuel Sarkodie
Lou Whitehead
Methodology research
Overview
Adaptive designs
Master protocols
Transforming IMID trials
Projects
Publications
News
Courses
Adaptive Designs and Multiple Testing Procedures
Leveraging External Information
Precision Medicine Clinical Trials
Contact
Light
Dark
Automatic
Methenamine hippurate compared with antibiotic prophylaxis to prevent recurrent urinary tract infections in women: the ALTAR non-inferiority RCT
Chris Harding
,
Thomas Chadwick
,
Tara Homer
,
Jan Lecouturier
,
Helen Mossop
,
Sonya Carnell
,
Will King
,
Alaa Abouhajar
,
Luke Vale
,
Gillian Watson
,
Rebecca Forbes
,
Stephanie Currer
,
Robert Pickard
,
Ian Eardley
,
Ian Pearce
,
Nikesh Thiruchelvam
,
Karen Guerrero
,
Katherine Walton
,
Zahid Hussain
,
Henry Lazarowicz
,
Ased Ali
May 2022
Cite
DOI
URL
Type
Journal article
Publication
Health Technology Assessment
Chadwick
Mossop
Related
Cost-effectiveness of methenamine hippurate compared with antibiotic prophylaxis for the management of recurrent urinary tract infections in secondary care: a multicentre, open-label, randomised, non-inferiority trial
Alternative to prophylactic antibiotics for the treatment of recurrent urinary tract infections in women: multicentre, open label, randomised, non-inferiority trial
ALternatives To prophylactic Antibiotics for the treatment of Recurrent urinary tract infection in women (ALTAR): Study protocol for a multicentre, pragmatic, patient-randomised, non-inferiority trial
Extracorporeal photopheresis (ECP) in the treatment of chronic lung allograft dysfunction (CLAD): a prospective, multicentre, open-label, randomised controlled trial studying the addition of ECP to standard care in the treatment of bilateral lung transplant patients with CLAD (E-CLAD UK)
The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer – a study protocol
Cite
×